Business Insider

ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for ...
PharmiWeb

ASLAN PHARMACEUTICALS ANNOUNCES PRICING OF $12.8 MILLION PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

Singapore, 3 December 2019 – ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has priced its ...
PharmiWeb

ASLAN PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

Singapore, 3 December 2019 – ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has commenced an underwritten ...
Nasdaq

New Data Presented on ASLAN’s varlitinib at ESMO 2019

SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of new ...
24/7 Wall St

How Aslan Pharma Is Capitalizing on Its Huge Atopic Dermatitis Success

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) has been on a ...
Stockhouse

ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

SINGAPORE, Sept. 19, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced late-breaking topline ...
Nasdaq

ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Strong Buy: Rationale Behind the Upgrade

ASLAN Pharmaceuticals Ltd. (ASLN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Business Insider

ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

SINGAPORE, April 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical stage oncology and immunology focused biopharmaceutical company developing novel therapeutics ...